Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransCode Therapeutics (RNAZ – Research Report) and Nyxoah (NYXH – Research Report).
Nyxoah (NYXH)
Robert W. Baird analyst David Rescott maintained a Hold rating on Nyxoah on May 14 and set a price target of EUR10.00. The company’s shares closed last Thursday at $10.00.
According to TipRanks.com, Rescott is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nyxoah with a $18.65 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RNAZ:
- Transcode Therapeutics board issues letter to shareholders
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
- Transcode announces FDA clearance to initiate Phase 1/2 trial of TTX-MC138
- TransCode Therapeutics Reports 2023 Results; Provides Business Update
- Transcode Therapeutics sees cash runway into late Q3/early 4Q24
